Delphia (USA)’s Filana Therapeutics FLNA Stock Holding History

Delphia (USA)’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,618	Closed	-$235K	–	352
2022 Q3	$235K	Buy	+5,618	New	+$152K	0.27%	167

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Delphia (USA)'s FLNA Position: Q4 2022 in Review

Delphia (USA) sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 5,618 shares — an estimated $235K sold.

Delphia (USA) first reported a position in FLNA in Q3 2022 and held it in 1 quarter. The position peaked at $235K in Q3 2022. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

Delphia (USA) reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
Delphia (USA) sold 5,618 Filana Therapeutics shares in Q4 2022, an estimated $235K.
Delphia (USA) first reported a position in Filana Therapeutics in Q3 2022 and held it in 1 quarter.
Delphia (USA)'s Filana Therapeutics position peaked at $235K in Q3 2022.
153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Delphia (USA)'s 13F filing for Q4 2022, filed 14 Feb 2023.